Analyst Price Targets — PMVP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 8, 2024 11:04 am | Jeff Jones | Oppenheimer | $6.00 | $1.75 | StreetInsider | Oppenheimer Upgrades PMV Pharmaceuticals Inc. (PMVP) to Outperform |
| April 11, 2024 7:46 pm | Kambiz Yazdi | Jefferies | $5.00 | $1.58 | TheFly | PMV Pharmaceuticals initiated with a Buy at Jefferies |
| November 17, 2022 6:10 am | — | H.C. Wainwright | $36.00 | $10.29 | Benzinga | HC Wainwright & Co. Maintains Buy on PMV Pharma, Lowers Price Target to $36 |
| June 9, 2022 8:01 am | — | Oppenheimer | $33.00 | $10.24 | Benzinga | Oppenheimer Maintains Outperform on PMV Pharma, Raises Price Target to $33 |
| May 24, 2022 10:18 am | — | Goldman Sachs | $25.00 | $14.09 | Benzinga | Goldman Sachs Maintains Buy on PMV Pharma, Lowers Price Target to $25 |
Latest News for PMVP
PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PMVP.
U.S. House Trading
No House trades found for PMVP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.